Voglinorm M Tablets (Voglibose + Metformin)

• Composition :
  Each tablet contains Voglibose 0.2mg/ 0.3mg+ Metformin 500 mg.
• Indications :
  As 2nd line treatment of type II Diabetes mellitus when diet, exercise and the single agent do not result in adequate glycaemic control.
• Pharmacodynamics :
  Voglibose is an alpha-glucosidase inhibitor which reduces intestinal absorption of starch,dextrin, and disaccharides by inhibiting the action of alpha-glucosidase in the intestinal brush border. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
• Dosage and administration :
  Twice daily orally
• Contraindications :
  Contraindicated in patients with known hypersensitivity to the drug, acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Contraindicated in case of renal dysfunction. temporarily discontinued in patients undergoing radiological studies.
• Precautions and warnings :
  Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake, while receiving metformin. Voglibose should be administered with caution to the following patients: patients with history of laparotomy or ileus; patients with chronic intestinal disease accompanied by disturbance in digestion and absorption; patients with aggravating symptoms due to increased generation of intestinal gas.
• Use in pregnancy, lactation & pediatrics :
  Shouldnot be used in pregnancy and lactation. Safety and effectiveness is not established in paediatric population
• Drug interactions :
  When voglibose is used in combination with derivative(s) of sulfonylamide, sulfonylurea or biguanide, or with insulin, hypoglycemic symptoms may occur. Metformin may result in suboptimal oral vitamin B12 absorption by competitively blocking the calcium dependent binding of the intrinsic factor vitamin B12 complex to its receptor.
• Adverse reactions :
  Nausea, diarrhoea, abdominal pain, constipation, vomiting, metallic taste in mouth have been reported with metformin therapy. When voglibose is used in combination with other antidiabetic drugs, hypoglycemia may occur.
• Therapy Area :
  Anti-Diabetic agents